医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Promega NanoBiT Complementation Assay Named a Top 10 Innovation

2015年12月04日 PM11:30
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

MADISON, Wis.

The Scientist named Promega NanoBiT™ (NanoLuc® Binary Technology) Assay as a Top 10 Innovation for 2015. This is the third Promega technology in four years named as a top innovation.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151204005425/en/

NanoBiT™ PPI Starter Systems contain materials required to build a NanoBiT assay. (Photo: Business W ...

NanoBiT™ PPI Starter Systems contain materials required to build a NanoBiT assay. (Photo: Business Wire)

NanoBiT is a clever structural complementation reporter based on NanoLuc, a novel luciferase derived from the deep sea shrimp, Oplophorus gracilirostris. Scientists can use the new NanoBiT to explore protein:protein interactions in living cells in real time, including tracking association and dissociation.

The new tool is helping advance the understanding of fundamental cellular biology in human diseases and can be used to monitor cellular interactions in a more biologically relevant, live-cell approach. Kathryn Luker, an academic researcher, is using NanoBiT in researching the role of chemokine receptor signaling in the mechanisms of primary and metastatic cancer. “Of the many luciferase complementation methods we have used, NanoBiT offers the best combination of strong signal, low background, small size and ATP-independence,” said Luker.

“This is definitely a great new tool for developing luminescence-based assays of many kinds,” added Luker. “Moreover, NanoBiT works well for imaging intracellular protein associations in live cells.”

Using plasmids that encode the NanoBiT complementation reporter, researchers can easily make fusion reporters with the proteins they are interested in studying. If their proteins do interact, the two subunits of NanoBiT are brought together to reform an active enzyme producing a bioluminescent signal. Scalable, plate-based format and directly proportional activity to signal make NanoBiT ideal for high-throughput screening.

Promega R&D engineered and optimized the 18kDa and 1kDa subunits of NanoBiT to be stable, with low self-affinity and an ultra-bright signal upon association. The result is a protein interactions detection system that is reversible and exhibits low interference. Experiments, therefore, can be conducted at native expression levels, and the complementation system emits light only when the two unique subunits properly reform the complete structure.

For more information on NanoBiT, please visit http://www.promega.com/NewNanoBiT.

To see how NanoBiT works, view this short video: http://www.promega.com/NanoBiTWorks.

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 3,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151204005425/en/

CONTACT

Promega Corporation
Penny Patterson, (608) 274-4330
Sr.
Director, Communications
penny.patterson@promega.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果
  • GenePeeks Expands Distribution to India with Exclusive Agreement with CORE Diagnostics